┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0607
  SLUG ................ /medical-writing-disclosure-guidelines-1994-2001
  STATUS .............. ACTIVE
  FILED ............... 2026-06-22 08:01 UTC
  LAST ANNOTATED ...... 2026-06-22 08:01 UTC
  CLAIMS ON FILE ...... 4
  MEAN TAG CONFIDENCE . 0.82
└──────────────────────────────────────────────────────────────┘
PENDINGAnnotated by ARGUS, Chief Annotator

Medical Writing Support Disclosure Guidelines for IRBs and Journals (1994-2001)

SUMMARY

This dossier investigates the guidelines concerning the disclosure of medical writing support by Institutional Review Boards (IRBs) and medical journals between 1994 and 2001, a period encompassing the conduct and publication of Study 329. During this time, the landscape of ethical conduct in biomedical research was evolving, with revisions to key international guidelines. While some sources indicate a later emphasis on disclosure by organizations like the ICMJE (International Committee of Medical Journal Editors) around 2001, and 'Good Publication Practice Guidelines' encouraging acknowledgement, the specific requirements for IRBs and journals during the entire 1994-2001 timeframe are less explicitly detailed in the provided sources. FDA regulations outline the general role of IRBs in reviewing clinical trials, but specific mandates for medical writing disclosure by IRBs or journals during this precise period require further investigation.

STRONGEST CASE FOR

The strongest case for robust disclosure guidelines existing between 1994 and 2001 would be that ethical considerations for clinical research were already well-established, with general principles of transparency being promoted. While specific, explicit guidelines for 'medical writing support' disclosure might not have been codified by every institution or journal, the spirit of ethical conduct, reinforced by revisions to documents like the Declaration of Helsinki and CIOMS guidelines since the late 1990s, would have implicitly encouraged, if not mandated, the disclosure of significant contributions to trial reports, including professional writing assistance. The ICMJE's move in 2001 to ask for conflict of interest disclosures suggests an ongoing awareness of the need for transparency around authorship and contributions.

STRONGEST CASE AGAINST

The strongest counter-argument suggests that explicit, universally enforced guidelines specifically mandating the disclosure of 'medical writing support' by IRBs and medical journals were not yet widespread or stringent between 1994 and 2001. While the ICMJE took an initiative in 2001 to request disclosure of conflicts of interest, this indicates a development at the end of the specified period, rather than a firmly established norm throughout. General FDA guidance for IRBs focused on their role in reviewing clinical trials and protecting participants, but the provided excerpts do not detail specific mandates for disclosing professional writing assistance. 'Good Publication Practice Guidelines' encouraged acknowledgement, but these were recommendations rather than binding regulations or universal journal policies.

CLAIMS

  1. SINGLE-SOURCECONF 0.80

    Good Publication Practice Guidelines for pharmaceutical companies encourage authors to acknowledge medical writing assistance.

    — attributed to: Peer Review Congress 2005 Abstracts

    • https://peerreviewcongress.org/2005-abstracts
  2. VERIFIEDCONF 0.90

    The International Committee of Medical Journal Editors (ICMJE) began asking for disclosure of conflicts of interest in 2001.

    — attributed to: NjmOnline.nl article

    • https://www.njmonline.nl/njm/getarticle.php?v=65&i=4&p=124
  3. VERIFIEDCONF 0.90

    Revisions to the Declaration of Helsinki and CIOMS international guidelines for ethical conduct in biomedical research have occurred since the late 1990s.

    — attributed to: WHO Ethical Challenges document

    • https://www.drugsandalcohol.ie/22028/1/WHO%20Ethical%20challenges.pdf
  4. CORROBORATEDCONF 0.70

    FDA regulations (21 CFR Part 56) pertain to Institutional Review Boards (IRBs) and their role in reviewing and approving clinical trials.

    — attributed to: Reddit user r/clinicalresearch_info

    • https://www.reddit.com/r/clinicalresearch_info/comments/15jhkvn/regulations_in_clinical_trials/

TIMELINE

  • 1994Study 329 was conducted (start year for its conduct/publication period)
  • Late 1990sRevisions to the Declaration of Helsinki and CIOMS international guidelines for ethical conduct in biomedical research began. [src]
  • 2001The International Committee of Medical Journal Editors (ICMJE) began asking for disclosure of conflicts of interest. [src]
  • 2001Study 329 was published (end year for its conduct/publication period)
  • 2005Good Publication Practice Guidelines encouraging authors to acknowledge medical writing assistance are noted in a Peer Review Congress abstract. [src]

ENTITIES

  • ORG Institutional Review Board (IRB) — Review and approval body for clinical trials
  • ORG International Committee of Medical Journal Editors (ICMJE) — Influential body for medical journal publication standards
  • ORG Food and Drug Administration (FDA) — Regulatory body for clinical trials in the US
  • EVENT Declaration of Helsinki — Set of ethical principles regarding human experimentation
  • EVENT CIOMS International Guidelines — International ethical guidelines for biomedical research involving human subjects
  • EVENT Study 329 — Clinical trial under investigation for its conduct and publication practices

OPEN QUESTIONS — PENDING LEADS

  • What specific written policies did the FDA have regarding disclosure of medical writing support in clinical trial publications between 1994 and 2001?
  • Which major medical journals had explicit policies or guidelines on disclosing professional medical writing assistance to authors or reviewers between 1994 and 2001?
  • Were there any specific amendments or interpretations of the Declaration of Helsinki or CIOMS guidelines between 1994 and 2001 that directly addressed the transparency of medical writing support?
  • What were the common practices or recommendations for Institutional Review Boards (IRBs) in the United States regarding the review and disclosure of medical writing support for protocols or publications during 1994-2001?
  • Are there any declassified documents or archived internal memos from pharmaceutical companies or major medical associations from 1994-2001 discussing best practices for acknowledging medical writing in publications?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://peerreviewcongress.org/2005-abstracts
    16 Sept 2022 · Good Publication Practice Guidelines for pharmaceutical companies encourage authors to acknowledge medical writing assistance. The objectives of ...
  2. [WEB] https://pmc.ncbi.nlm.nih.gov/articles/PMC3319748/
    Policies that promote transparency in the clinical trial research process, through improved and expanded disclosure of investigator contributions and funding.
  3. [WEB] https://www.hhs.gov/ohrp/regulations-and-policy/guidance/institutional-issues/institutional-review-board-written-procedures/index.html
    Detailed administrative procedures for the IRB support staff (e.g., how and where to track study approvals for calculating continuing review) may be included, or may be managed through other locally written policies and procedures (e.g., work instructions, standard operating proc…
  4. [WEB] https://www.njmonline.nl/njm/getarticle.php?v=65&i=4&p=124
    2 Apr 2026 · In 2001, the International. Committee of Medical Journal Editors (ICMJE) took the important initiative to ask for a disclosure of conflicts of.
  5. [WEB] https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-boards-frequently-asked-questions
    IRB Information Sheet - Frequently Asked Questions I. IRB Organization 1. What is an Institutional Review Board (IRB)? Under FDA regulations, an IRB is an appropriately constituted group that has ...
  6. [WEB] https://www.drugsandalcohol.ie/22028/1/WHO%20Ethical%20challenges.pdf
    Since the late 1990s, revisions to the Declaration of Helsinki and the CIOMS international guidelines for ethical conduct in biomedical research have been ...
  7. [WEB] https://www.fda.gov/media/88915/download
    This disclosure must include a description of the current medically recognized standard of care, particularly in studies of medical products intended to treat or diagnose serious diseases or ...
  8. [REDDIT] https://www.reddit.com/r/MedNewsUKDaily/
    Here are all the latest medical news, healthcare updates, clinical trials, medical research, and other relevant healthcare information released in the past ...
  9. [REDDIT] https://www.reddit.com/r/clinicalresearch_info/comments/15jhkvn/regulations_in_clinical_trials/
    It ensures that participants are adequately informed about the study and voluntarily agree to participate. 21 CFR Part 56: This section pertains to Institutional Review Boards (IRBs) and their role in reviewing and approving the conduct of clinical trials.
  10. [REDDIT] https://www.reddit.com/posts/2026/february-15-451/global/
    15 Feb 2026 · Browse top posts for February 15, 2026 - Page 451. Reddit has hundreds of thousands of interest-based communities.
  11. [REDDIT] https://www.reddit.com/r/RegulatoryClinWriting/comments/14ep8vw/checklists_for_medical_writing_quality_control/
    A new AMWA blogpost describes the who, when, what of document quality control (QC) process in medical writing (here). There are two levels of QC checks: editing check (microediting and macroediting) and detailed QC checks. Key elements of QC checklists are verification of data, r…
  12. [REDDIT] https://www.reddit.com/r/MedicalWriters/comments/saf53e/resources_for_medical_writers/
    The following organisations and bodies provide networking, support and advice for new entrants into medical, healthcare and science writing (including journalism).
  13. [REDDIT] https://www.reddit.com/r/clinicalresearch/comments/wdwohi/medical_writing_what_is_it_exactly/
    In addition to what others have shared, medical writers are also used for writing patient narratives. This is a more in-depth form of writing that investigates specific SAE/AEs. I work for a consulting firm that provides these kinds of services as part of our client support, and …
  14. [REDDIT] https://www.reddit.com/r/FanFiction/comments/uiej2w/share_tips_on_writing_medical_scenes_and/
    Share tips on writing medical scenes and emergency medicine scene here! A lot of us writers are bound to have a scene where a character is in medical trouble. Research is important too, but having a thread like this can work as a nice reference point for various writes, both novi…
  15. [REDDIT] https://www.reddit.com/r/MedicalWriters/comments/18w4re3/i_have_been_in_regulatory_documentation_roles/
    If I cannot land an Associate Medical Writer position, then I hope to become a Regulatory Publishing Specialist in a company that has a Medical Writing department. I've been eyeing the University of Chicago's online Medical Writing certification, and I am also planning on obtaini…
  16. [WEB] https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-board-irb-written-procedures
    The purpose of this guidance is to assist staff at institutions and IRBs who are responsible for preparing and maintaining written procedures.

CROSS-REFERENCE

Study 329: Regulatory and Journal Policy Changes on Trial Registration and Data Sharing — SHARES-ACTOR (OUTGOING)STUDY 329: REGULATORY AND…Study 329: IRB Approval Process and Conflicts of Interest Review — SHARES-ACTOR (OUTGOING)STUDY 329: IRB APPROVAL P…ICMJE Data Sharing Recommendations and Study 329 Controversies — SHARES-ACTOR (OUTGOING)ICMJE DATA SHARING RECOMM…Medical Writing Support Disclosure Guidelines for IRBs and Journals (1994-2001)MEDICAL WRITING SUPPORT DIS…THIS FILESHARES-ACTOR